PS-121 Model for advising on interactions and adverse reactions of tyrosine kinase inhibitor treatment
BackgroundTyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of TKIs both take place in Hospital Pharmacies. Primary Care physicians (GPs) do not have very much information about either these drugs or patient...
Saved in:
Published in | European journal of hospital pharmacy. Science and practice Vol. 22; no. Suppl 1; p. A184 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BMJ Publishing Group LTD
01.03.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BackgroundTyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of TKIs both take place in Hospital Pharmacies. Primary Care physicians (GPs) do not have very much information about either these drugs or patients on TKI treatment.PurposeTo describe a model for giving advice with recommendations about interactions and adverse reactions of TKIs, to provide support and information for PC physicians.Material and methodsPatients on TKI treatment were identified by the APD-ATHOS Prisma and Oncofarm software. The databases were searched for adverse reactions and interactions due to TKIs, together with their management. We selected the most common adverse reactions and interactions, including those that could cause the patients to consult their general practitioner. Then, we made a document with all the information and PC pharmacists established a link between this document and the Electronic Clinical History of each patient to enable GPs to identify patients who were on TKI treatment and also recommendations about their management.Results44 patients were identified (37 with imatinib, 4 with dasatinib and 3 with nilotinib). 29 adverse reactions were found (9 common to all 3 TKIs, plus 8 with dasatinib, 8 with nilotinib and 4 with imatinib). Interactions were classified into: drugs that increase or reduce the effects of TKIs and drugs whose effects and toxicity are increased or decreased by TKIs. The most significant interactions were: imatinib-simvastatin, imatinib-acetaminophen, imatinib-ibuprofen; nilotinib/dasatinib-proton pump inhibitors, nilotinib/dasatinib-histamine-2 receptor antagonists, nilotinib/dasatinib-drugs that prolong the QT interval, nilotinib/dasatinib-oral anticoagulants and dasatinib-food.ConclusionThe way of giving advice should help GPs to identify and manage frequent adverse reactions and interactions of TKIs. This process will be repeated for other oral anti-cancer drugs. Further studies are necessary to confirm the usefulness of this tool.References and/or acknowledgementsNo conflict of interest. |
---|---|
AbstractList | BackgroundTyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of TKIs both take place in Hospital Pharmacies. Primary Care physicians (GPs) do not have very much information about either these drugs or patients on TKI treatment.PurposeTo describe a model for giving advice with recommendations about interactions and adverse reactions of TKIs, to provide support and information for PC physicians.Material and methodsPatients on TKI treatment were identified by the APD-ATHOS Prisma and Oncofarm software. The databases were searched for adverse reactions and interactions due to TKIs, together with their management. We selected the most common adverse reactions and interactions, including those that could cause the patients to consult their general practitioner. Then, we made a document with all the information and PC pharmacists established a link between this document and the Electronic Clinical History of each patient to enable GPs to identify patients who were on TKI treatment and also recommendations about their management.Results44 patients were identified (37 with imatinib, 4 with dasatinib and 3 with nilotinib). 29 adverse reactions were found (9 common to all 3 TKIs, plus 8 with dasatinib, 8 with nilotinib and 4 with imatinib). Interactions were classified into: drugs that increase or reduce the effects of TKIs and drugs whose effects and toxicity are increased or decreased by TKIs. The most significant interactions were: imatinib-simvastatin, imatinib-acetaminophen, imatinib-ibuprofen; nilotinib/dasatinib-proton pump inhibitors, nilotinib/dasatinib-histamine-2 receptor antagonists, nilotinib/dasatinib-drugs that prolong the QT interval, nilotinib/dasatinib-oral anticoagulants and dasatinib-food.ConclusionThe way of giving advice should help GPs to identify and manage frequent adverse reactions and interactions of TKIs. This process will be repeated for other oral anti-cancer drugs. Further studies are necessary to confirm the usefulness of this tool.References and/or acknowledgementsNo conflict of interest. Background Tyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of TKIs both take place in Hospital Pharmacies. Primary Care physicians (GPs) do not have very much information about either these drugs or patients on TKI treatment. Purpose To describe a model for giving advice with recommendations about interactions and adverse reactions of TKIs, to provide support and information for PC physicians. Material and methods Patients on TKI treatment were identified by the APD-ATHOS Prisma and Oncofarm software. The databases were searched for adverse reactions and interactions due to TKIs, together with their management. We selected the most common adverse reactions and interactions, including those that could cause the patients to consult their general practitioner. Then, we made a document with all the information and PC pharmacists established a link between this document and the Electronic Clinical History of each patient to enable GPs to identify patients who were on TKI treatment and also recommendations about their management. Results 44 patients were identified (37 with imatinib, 4 with dasatinib and 3 with nilotinib). 29 adverse reactions were found (9 common to all 3 TKIs, plus 8 with dasatinib, 8 with nilotinib and 4 with imatinib). Interactions were classified into: drugs that increase or reduce the effects of TKIs and drugs whose effects and toxicity are increased or decreased by TKIs. The most significant interactions were: imatinib-simvastatin, imatinib-acetaminophen, imatinib-ibuprofen; nilotinib/dasatinib-proton pump inhibitors, nilotinib/dasatinib-histamine-2 receptor antagonists, nilotinib/dasatinib-drugs that prolong the QT interval, nilotinib/dasatinib-oral anticoagulants and dasatinib-food. Conclusion The way of giving advice should help GPs to identify and manage frequent adverse reactions and interactions of TKIs. This process will be repeated for other oral anti-cancer drugs. Further studies are necessary to confirm the usefulness of this tool. References and/or acknowledgements No conflict of interest. |
Author | De Travecedo, M Gomez Garcia Bonilla, A Gomez Germa, P Calvo, Y Almendral Vicente, M Gazquez Perez, R Gomez De Rueda, F Sierra Sanchez, J Gonzalez Rosa, V Gavira Moreno, R Jimenez Pichardo, L |
Author_xml | – sequence: 1 givenname: R surname: Gazquez Perez fullname: Gazquez Perez, R organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 2 givenname: A surname: Garcia Bonilla fullname: Garcia Bonilla, A organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 3 givenname: R surname: Gavira Moreno fullname: Gavira Moreno, R organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 4 givenname: J surname: Sierra Sanchez fullname: Sierra Sanchez, J organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 5 givenname: V surname: Gonzalez Rosa fullname: Gonzalez Rosa, V organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 6 givenname: F surname: Gomez De Rueda fullname: Gomez De Rueda, F organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 7 givenname: L surname: Jimenez Pichardo fullname: Jimenez Pichardo, L organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 8 givenname: P surname: Gomez Germa fullname: Gomez Germa, P organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 9 givenname: M Gomez surname: De Travecedo fullname: De Travecedo, M Gomez organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 10 givenname: Y surname: Calvo fullname: Calvo, Y organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain – sequence: 11 givenname: M surname: Almendral Vicente fullname: Almendral Vicente, M organization: Hospital Sas Jerez de La Frontera, Primary Care Pharmacy, Jerez de La Frontera, Spain |
BookMark | eNp9kMtKAzEUhoNUsNa-Q8D11FwnzVKKN6goqOuQzCROaiepmVTozo0v6pM4Q61LV-dw_suB7xSMQgwWAIjRDGNaXthVs2l0aguCMC8QQiWVM8bIERgTxEQhZclGfzsvT8C067xBnNK5ZFSOQfP4VGCCvz-_7mNt19DFBHX94TsfXmEM0Idsk66yj6GDOtSDaFNnYbKHa3Qw71LsExa--aB70YfGG5_7rtz7cmtDPgPHTq87O_2dE_ByffW8uC2WDzd3i8tlYTBCpKjmmlFaMSKYsa4UQpdGOsatwCVzDFeIM43qiqK54I6SWmhsuNWydrhPGToB5_veTYrvW9tltYrbFPqXinBOBKdMkH9diElOEKGDi-5dpl2pTfKtTjuFkRrYqwN7NbBXe_aqZ09_AEGafA0 |
ContentType | Journal Article |
Copyright | 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions Copyright: 2015 © 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2015 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
Copyright_xml | – notice: 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: Copyright: 2015 © 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions – notice: 2015 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions |
DBID | 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR BTHHO CCPQU FYUFA GHDGH K9. PQEST PQQKQ PQUKI PRINS |
DOI | 10.1136/ejhpharm-2015-000639.442 |
DatabaseName | ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central BMJ Journals ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China |
DatabaseTitle | ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition BMJ Journals ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest One Academic Eastern Edition ProQuest One Academic Eastern Edition |
Database_xml | – sequence: 1 dbid: 7X7 name: ProQuest Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2047-9964 |
EndPage | A184 |
GroupedDBID | 0R~ 3V. 53G 7X7 8FI 8FJ AAYAA ABKRM ABUWG ABVAJ ABWEH ADBBV ADMRH AFKRA AHMBA AHQMW AJYBZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BENPR BPHCQ BTHHO C45 CCPQU CXRWF EBS EJD FYUFA H13 HAJ HMCUK HYE OK1 OVD PQQKQ PROAC RHI RMJ RPM TEORI UKHRP 7XB 8FK K9. PQEST PQUKI PRINS |
ID | FETCH-LOGICAL-b1002-c8a433c4274bef677a6b9f45e7164f41c054a0dc30875f32d7a1b5ea9df1c42b3 |
IEDL.DBID | BENPR |
ISSN | 2047-9956 |
IngestDate | Fri Sep 13 01:53:47 EDT 2024 Fri Sep 13 04:30:46 EDT 2024 Wed Aug 21 03:28:42 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b1002-c8a433c4274bef677a6b9f45e7164f41c054a0dc30875f32d7a1b5ea9df1c42b3 |
PQID | 2049520232 |
PQPubID | 2040966 |
ParticipantIDs | proquest_journals_2552753472 proquest_journals_2049520232 bmj_primary_10_1136_ejhpharm_2015_000639_442 |
PublicationCentury | 2000 |
PublicationDate | 20150300 20150301 |
PublicationDateYYYYMMDD | 2015-03-01 |
PublicationDate_xml | – month: 03 year: 2015 text: 20150300 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | European journal of hospital pharmacy. Science and practice |
PublicationYear | 2015 |
Publisher | BMJ Publishing Group LTD |
Publisher_xml | – name: BMJ Publishing Group LTD |
SSID | ssib053389439 ssj0000605265 ssib018287486 |
Score | 1.9709253 |
Snippet | BackgroundTyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of... Background Tyrosine Kinase Inhibitors (TKIs) are drugs that cause significant adverse reactions and interactions in patients. Prescription and dispensing of... |
SourceID | proquest bmj |
SourceType | Aggregation Database Publisher |
StartPage | A184 |
SubjectTerms | Drugs Family physicians |
Title | PS-121 Model for advising on interactions and adverse reactions of tyrosine kinase inhibitor treatment |
URI | http://dx.doi.org/10.1136/ejhpharm-2015-000639.442 https://www.proquest.com/docview/2049520232/abstract/ https://www.proquest.com/docview/2552753472/abstract/ |
Volume | 22 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV07T8MwELb6WFgQCBCFUnlgJDR27KSZEKBWFRJVBVTqFtmOQ1sgLW0Z2Fj4o_wS7vIoA4I1jhXpfLn77nz3HSGnrg1dK43raHBWjuDWd0JfMId1TMyNsGGYJdxuB35_JG7Gclwh_bIXBssqS5uYGep4bjBH3uZIFSY9EfC20pgFMOv2xeLVwflReM9aDNOokjpnAi9s61fdwfCu1C2WEbv_UKUBykHm8XCTj3F9ZD7BikeO5AXY8FkW_nh-284mC6SSBqVi0skd-7nA-e5V_TL7Zccz59TbIdsFqqSXuRrskopN98hkeO8wzr4-PnHg2TMFeEpVjM3k6SOdpxSZIpZ5X8OKqjTGRQCDlgKOLJ7OE7p-Bz8KUJQ-TVPweLBrMtVgBpZ0U6O-T0a97sN13ykGK8CJoAU0HSU8zwiISLVN_CBQvg4TIS0GT4lgBnCccmODbIEy8XgcKKalVWGcMNilvQNSS-epPSQ05EZ2MpZ5JQVXHgTUPFHGdRV8QJm4Qc5AQNEip86IspDD86NSnhHKM8rlGYE8G6RZSjIqfqYVvANRHI55_2N5oxlH_y8fk638-LCCrElq6-WbPQFIsdYtUg3GQavQmW8uXcdn |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,33779,43345,43840,74102,74659 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELWgDLAgECAKBTwwEho7dtJMCCGqAm2FRCt1ixzHoS2QlLYMbCz8UX4Jd_liQLDGsSI923fvLud3hJzaxreN1LYVgrOyBDeu5buCWaylI66F8f0s4dbru52huB3JUZFwWxRllaVNzAx1lGrMkTc5SoVJR3j8YvZqYdco_LtatNBYJWvCcQSW9Hmjyp2yTMz9Rx4NmA2qjftVDsZ2Ue0Eqxw5ChbgJc-y2Mdxm2Y6nqF8NGwkJq3cmZ8L7Om-Gr5Mf9nuzCG1t8hmwSTpZb7022TFJDtkfP9gMc6-Pj6xydkzBUpKVYQXyJNHmiYU1SHm-V2GBVVJhINAAA0F7lg8TWO6fAffCfSTPk0S8HIwazwJ4ejPaVWXvkuG7evBVccqminAKqDV0y0FEGkBUWhoYtfzlBv6sZAGA6ZYMA3cTdmRRoVAGTs88hQLpVF-FDOYFTp7pJakidkn1OdatjJleSUFVw4E0TxW2rYVfEDpqE7OAKBglstlBFmY4bhBiWeAeAY5ngHgWSeNEsmgOEALeAciN2zt_sdwtRsO_h8-IeudQa8bdG_6d4dkI19KrCBrkNpy_maOgFIsw-Ns33wDp-bETQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwELVokRALAgGiUMADI6GxYyfNhBBQla-qElTqFjmOQ1sgKW0Z2Fj4o_wS7vLFgGCNY0U6n-_eOc_vCDmyjW8bqW0rhGRlCW5cy3cFs1hbR1wL4_vZgdtdz-0OxPVQDgv-07ygVZYxMQvUUarxjLzFUSpMOsLjrbigRfQvOqfTVws7SOGf1qKdRo0sQ5a0sZuBN6xSK8uE3X-k0gDloPK4X53H2C4qnyDjkaN4AV74LIk_jtsyk9EUpaTBqZi08sR-IrC_ey18mfyK41ly6qyTtQJV0rPcDTbIkkk2yah_bzHOvj4-seHZMwV4SlWEl8mTR5omFJUiZvm9hjlVSYSDAAYNBRxZPE1juniHPApQlD6NE8h4MGs0DiEMzGjFUd8ig87lw3nXKhorwIpgBNRtJRxHC6hIQxO7nqfc0I-FNFg8xYJpwHHKjjSqBcrY4ZGnWCiN8qOYwazQ2Sb1JE3MDqE-17KdqcwrKbhyoKDmsdK2reADSkcNcgwGCqa5dEaQlRyOG5T2DNCeQW7PAOzZIM3SkkGxmebwDlRx2Ob9j-HKM3b_Hz4kK-Aywe1V72aPrOYriWSyJqkvZm9mH9DFIjzI3OYb4FLIeQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PS-121%E2%80%85Model+for+advising+on+interactions+and+adverse+reactions+of+tyrosine+kinase+inhibitor+treatment&rft.jtitle=European+journal+of+hospital+pharmacy.+Science+and+practice&rft.au=R+Gazquez+Perez&rft.au=A+Garcia+Bonilla&rft.au=Moreno%2C+R+Gavira&rft.au=J+Sierra+Sanchez&rft.date=2015-03-01&rft.pub=BMJ+Publishing+Group+LTD&rft.issn=2047-9956&rft.eissn=2047-9964&rft.volume=22&rft.issue=Suppl+1&rft.spage=A184&rft.epage=A184&rft_id=info:doi/10.1136%2Fejhpharm-2015-000639.442&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9956&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9956&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9956&client=summon |